Difference between revisions of "Zanubrutinib (Brukinsa)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
| + | *[[Waldenström macroglobulinemia]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 28: | Line 29: | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
| + | [[Category:Waldenström macroglobulinemia medications]] | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
Revision as of 13:32, 12 November 2020
General information
Class/mechanism: BTK inhibitor
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 11/14/2019: Granted accelerated approval for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Also known as
- Code name: BGB-3111
- Brand name: Brukinsa